Pharmacokinetic Comparison of Two Oral Mesalazine Formulations in Healthy Volunteers Under Fed Conditions for Chronic Idiopathic Inflammatory Bowel Disease

The primary objective of this study is to compare the **bioavailability** of two oral formulations of **mesalazine** in healthy volunteers under fed conditions. This is clinically relevant as mesalazine is commonly used in the management of **chronic idiopathic inflammatory bowel disease**, and understanding its bioavailability can inform dosing strategies and improve therapeutic outcomes.

The clinical trial involves participants diagnosed with **chronic idiopathic inflammatory bowel disease**. The study population includes both male and female subjects, with an age range of 18 to 65 years. The general health status of participants is not specified, and the sponsor has not provided information regarding the total number of participants. The trial population was selected without targeting any vulnerable groups. Relevant lifestyle considerations such as diet, physical activity, or habits have not been detailed. Key inclusion or exclusion criteria have not been disclosed by the sponsor.

The clinical trial is designed to evaluate the **bioavailability** of two oral formulations of mesalazine in healthy volunteers under fed conditions. This study is a Phase 3, randomized, double-blind, controlled trial, which aims to provide comparative data on the pharmacokinetic profiles of the formulations. The trial is expected to commence recruitment on January 13, 2025, and conclude by March 30, 2025. Participants will be involved in the study for a duration that includes an initial screening visit, multiple follow-up visits, and an end-of-study visit.

The sequence of study visits begins with the inclusion (screening) visit, where eligibility is assessed based on predefined criteria. Following successful screening, participants will be randomized to receive one of the two formulations. The follow-up visits are scheduled to monitor the participants' health status, adherence to the study protocol, and to collect necessary data for the evaluation of the primary and secondary endpoints. The end-of-study visit will involve a final assessment of the participants' health and the collection of any remaining data.

Participant involvement is expected to last until the end of the study period unless conditions arise that necessitate early termination. Such conditions may include adverse events, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it has been designated as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this clinical trial, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used alongside the experimental medication. The absence of such information suggests that the trial may focus solely on the experimental treatment, although this cannot be confirmed without further details.

Details regarding the **participant compliance monitoring** and specific **dosing schedules** are not included in the provided data. The lack of information on these aspects indicates that additional documentation or resources may be necessary to fully understand the trial's design and implementation.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on January 13, 2025, with an estimated completion date of March 30, 2025. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured protocol to ensure the collection and analysis of efficacy data is consistent and reliable. The trial phase indicates a focus on evaluating the effectiveness of the intervention in a larger population, typically involving a comparison to standard treatments or a placebo. The absence of specific endpoints or measurement tools in the provided data suggests that these details will be outlined in the full trial protocol, which will guide the systematic assessment of efficacy throughout the study duration.